Cleary J D, Hayman J, Sherwood J, Lasala G P, Piazza-Hepp T
School of Pharmacy, University of Mississippi, Jackson 39216.
Ann Pharmacother. 1993 Jun;27(6):715-9. doi: 10.1177/106002809302700607.
To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population. Treatment is also presented.
Hospital.
Two infants and three children inpatients receiving amphotericin B.
Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of amphotericin B. Cardiac arrest occurred in all patients, and four patients died. A detailed description of the cardiac event is provided for one patient who was on a cardiac monitor during the adverse reaction. Hydrocortisone prophylaxis and verapamil therapy were the primary therapies used in patient 1 (the only survivor). Evaluation of the literature provides substantial evidence for the use of hydrocortisone in prevention of cardiac arrhythmias.
Amphotericin B overdose can be fatal in children and infants. The presentation in humans appears similar to that in dogs where cardiac arrhythmias occurred at doses of 5-15 mg/kg. Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses. Animal studies are necessary to evaluate this observation and potential disadvantages of hydrocortisone usage.
